Webcast CME

Biologic Therapies VII: Precision Medicine in the Biologic Era


Pre-Rheumatoid Arthritis:
Can We Define It and Prevent Its Progression?

Print this Content

Release Date:   July 12, 2017
Expiration Date:   July 12, 2019

Estimated Time of Completion:   1 hour

Description

Biologic Therapies VII: Precision Medicine in the Biologic Era online series brings together world leaders in immune-based therapies and addresses cutting-edge translational immunology and the latest data on biologic therapeutics.

This webcast reviews RA-related biomarkers in patients prior to the first development of clinically apparent arthritis. The role of the mucosal immune system in the initial development of antibodies to citrullinated protein/peptide antigens will be explained. The evolving science in preclinical RA and management of high risk individuals for future RA will also be discussed.

Learning Objectives

  1. Describe the evolution and timing of appearance of RA-related biomarkers in the seropositive disease subset of patients prior to the first development of clinically apparent arthritis.
  2. Explain the postulated role of the mucosal immune system in the initial development of antibodies to citrullinated protein/peptide antigens (ACPA).
  3. Devise a new therapeutic and diagnostic paradigm that incorporates the evolving science in preclinical RA and will drive the management of individuals who are at high risk for future RA.

Target Audience

The online series is designed for rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, and associated allied health practitioners, including nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and inflammatory disorders.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Activity Directors and Faculty

Activity Directors

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

M. Elaine Husni, MD, MPH
Director, Arthritis and Musculoskeletal Treatment Center
Vice Chair, Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Faculty

V. Michael Holers, MD
Scoville Professor and Head, Division of Rheumatology
Departments of Medicine and Immunology
University of Colorado Anschutz
Medical Campus
Aurora, CO

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:


Leonard H. Calabrese, DO
  AbbVie Pharmaceuticals; Bristol-Myers Squibb;
Genentech/ Roche; Janssen
Consulting; Teaching and Speaking
  GlaxoSmithKline; Pfizer, Inc.; UCB Consulting
  Crescendo Teaching and Speaking
V. Michael Holers, MD
  Janssen Independent contractor (including contracted research)
M. Elaine Husni, MD, MPH
  AbbVie Pharmaceuticals; Genentech; Janssen Consulting
  Amgen; Bristol-Myers Squibb; Genzyme/Sanofi; Lilly, Regeneron Consulting;
Membership on advisory committee or review panels
  Novartis Pharmaceuticals Consulting; Teaching and Speaking
  Pfizer, Inc. Membership on advisory committee or review panels

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of this activity from:

AbbVie, Inc.
Amgen, Inc.
Bristol-Myers Squibb Co.
Celgene Corporation
Crescendo Bioscience, Inc.
Genentech
Janssen Scientific Affairs, LLC
Novartis Pharmaceuticals Corporation
UCB, Inc.

This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education
and the R.J. Fasenmyer Center for Clinical Immunology.